{"id":"https://openalex.org/W1761050310","doi":null,"title":"Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.","display_name":"Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.","alternate_titles":[],"publication_year":2003,"publication_date":"2003-10-01","ids":{"openalex":"https://openalex.org/W1761050310","mag":"1761050310","pmid":"https://pubmed.ncbi.nlm.nih.gov/14555307"},"language":"en","primary_location":{"id":"pmid:14555307","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/14555307","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Haematologica","raw_type":"Clinical Trial"},"parent_works":[],"lineage":["https://openalex.org/W1761050310"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["doaj","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018111458","display_name":"Francisco Cervantes","orcid":"https://orcid.org/0000-0003-2664-8131","observed_orcids":["https://orcid.org/0000-0003-2664-8131"]},"institutions":[{"id":"https://openalex.org/I4210115097","display_name":"Hospital Cl\u00ednic de Barcelona","ror":"https://ror.org/02a2kzf50","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210115097"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Francisco Cervantes","raw_affiliation_strings":["Hematology Department, Hospital Cl\u00ednic, Villarroel 170, 08036 Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology Department, Hospital Cl\u00ednic, Villarroel 170, 08036 Barcelona, Spain","institution_ids":["https://openalex.org/I4210115097"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070420697","display_name":"Juan Carlos Hern\u00e1ndez\u2010Boluda","orcid":"https://orcid.org/0000-0002-4289-3113","observed_orcids":["https://orcid.org/0000-0002-4289-3113"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Juan-Carlos Hern\u00e1ndez-Boluda","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110273040","display_name":"J. L. Steegmann","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Juan-Luis Steegmann","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110450902","display_name":"Eulogio Conde","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Eulogio Conde","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000389588","display_name":"Alberto \u00c1lvarez\u2010Larr\u00e1n","orcid":"https://orcid.org/0000-0001-6387-4619","observed_orcids":["https://orcid.org/0000-0001-6387-4619"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Alberto Alvarez-Larr\u00e1n","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010881749","display_name":"Javier L\u00f3pez\u2010Jim\u00e9nez","orcid":"https://orcid.org/0000-0002-2969-3002","observed_orcids":["https://orcid.org/0000-0002-2969-3002"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Javier L\u00f3pez-Jim\u00e9nez","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103182057","display_name":"Santiago Osorio","orcid":"https://orcid.org/0000-0002-6745-0490","observed_orcids":["https://orcid.org/0000-0002-6745-0490","https://orcid.org/0009-0007-2801-4219"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Santiago Osorio","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030976413","display_name":"Luc\u00eda Villal\u00f3n","orcid":"https://orcid.org/0000-0002-3506-1810","observed_orcids":["https://orcid.org/0000-0002-3506-1810"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Luc\u00eda Villal\u00f3n","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069945713","display_name":"Mireia Cam\u00f3s","orcid":"https://orcid.org/0000-0003-3658-7942","observed_orcids":["https://orcid.org/0000-0003-3658-7942"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mireia Cam\u00f3s","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114122050","display_name":"Javier Garc\u00eda-Conde","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Javier Garc\u00eda-Conde","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5110901630","display_name":"Jes\u00fas Odriozola","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jes\u00fas Odriozola","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.2491,"has_fulltext":false,"cited_by_count":50,"citation_normalized_percentile":{"value":0.87520223,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":97},"biblio":{"volume":"88","issue":"10","first_page":"1117","last_page":"1122"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/imatinib-mesylate","display_name":"imatinib mesylate","score":0.9980000257492065},{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.8999999761581421},{"id":"https://openalex.org/keywords/chronic-phase","display_name":"chronic phase","score":0.7879999876022339},{"id":"https://openalex.org/keywords/interferon-resistance","display_name":"interferon resistance","score":0.8799999952316284},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7139999866485596},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.8840000033378601},{"id":"https://openalex.org/keywords/cytogenetic-response","display_name":"cytogenetic response","score":0.9330000281333923},{"id":"https://openalex.org/keywords/hematological-response","display_name":"hematologic response","score":0.8619999885559082},{"id":"https://openalex.org/keywords/platelet-count","display_name":"platelet count","score":0.8230000138282776},{"id":"https://openalex.org/keywords/sokal-risk-score","display_name":"Sokal risk score","score":0.8040000200271606},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.6389999985694885},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.7289999723434448}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8365898132324219},{"id":"https://openalex.org/C3019892230","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib mesylate","level":4,"score":0.8225499391555786},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7882668972015381},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.7141013145446777},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.6950413584709167},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.6417087912559509},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.5827317833900452},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.5741019248962402},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3590524196624756},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3391157388687134},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3233506977558136},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2775859832763672}],"mesh":[{"descriptor_ui":"D000068877","descriptor_name":"Imatinib Mesylate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004342","descriptor_name":"Drug Hypersensitivity","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007372","descriptor_name":"Interferons","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D007372","descriptor_name":"Interferons","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D007372","descriptor_name":"Interferons","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D013030","descriptor_name":"Spain","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015466","descriptor_name":"Leukemia, Myeloid, Chronic-Phase","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015466","descriptor_name":"Leukemia, Myeloid, Chronic-Phase","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"pmid:14555307","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/14555307","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Haematologica","raw_type":"Clinical Trial"},{"id":"pmh:oai:doaj.org/article:d481fb2878f3437e8f90fb47f5f27593","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/d481fb2878f3437e8f90fb47f5f27593","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Haematologica, Vol 88, Iss 10 (2003)","raw_type":"article"},{"id":"mag:1761050310","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/14555307","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":17,"referenced_works":["https://openalex.org/W60081501","https://openalex.org/W1430390330","https://openalex.org/W1510546584","https://openalex.org/W1972804480","https://openalex.org/W1998593414","https://openalex.org/W2011474502","https://openalex.org/W2028959752","https://openalex.org/W2039045990","https://openalex.org/W2039978091","https://openalex.org/W2076372887","https://openalex.org/W2088033042","https://openalex.org/W2091849791","https://openalex.org/W2103072940","https://openalex.org/W2128738046","https://openalex.org/W2304674089","https://openalex.org/W2329648702","https://openalex.org/W2337277825"],"related_works":["https://openalex.org/W2416981963","https://openalex.org/W1964358866","https://openalex.org/W2159975218","https://openalex.org/W2107218745","https://openalex.org/W2157743993","https://openalex.org/W1542926909","https://openalex.org/W2107268345","https://openalex.org/W2088646795","https://openalex.org/W3028919538","https://openalex.org/W2569514347"],"abstract_inverted_index":{"BACKGROUND":[0],"AND":[1,46,233],"OBJECTIVES:":[2],"Imatinib":[3,235],"mesylate":[4],"has":[5],"recently":[6],"been":[7],"shown":[8],"to":[9,31,61,160,246,264],"be":[10],"highly":[11,237],"effective":[12,238],"in":[13,24,110,123,140,213,239,249,256],"chronic-phase":[14,25,54,240],"chronic":[15],"myeloid":[16],"leukemia":[17],"(CML).":[18],"The":[19,80,162],"results":[20],"of":[21,112,128,145,155,164,168,205],"imatinib":[22,100],"treatment":[23,151,194,261],"CML":[26,55,241],"patients":[27,52,129,149,242],"resistant":[28,56,243],"or":[29,58,244],"intolerant":[30,59,245],"interferon":[32],"(IFN)":[33],"and":[34,40,50,71,95,117,126,137,143,182,193,217,255],"the":[35],"factors":[36,68],"predicting":[37],"therapeutic":[38],"response":[39,70,107,226],"progression-free":[41,165,230],"survival":[42,166],"were":[43,63,74,121,199],"analyzed.":[44],"DESIGN":[45],"METHODS:":[47],"One":[48],"hundred":[49],"fifty":[51],"with":[53,65,171,201,251],"(n=111)":[57],"(n=39)":[60],"IFN":[62,90],"treated":[64],"imatinib.":[66],"Prognostic":[67],"for":[69,152],"disease":[72],"progression":[73],"assessed":[75],"by":[76],"multivariate":[77],"analysis.":[78],"RESULTS:":[79],"median":[81,89,96,154],"time":[82],"from":[83,98],"diagnosis":[84],"was":[85,108,174],"43":[86],"months":[87,93,102,181],"(0.5-188),":[88],"therapy":[91],"21.5":[92],"(0.5-140)":[94],"follow-up":[97],"starting":[99],"13.6":[101],"(range:":[103],"3-23).":[104],"Complete":[105],"hematologic":[106],"achieved":[109],"96":[111],"97":[113],"patients.":[114],"Complete,":[115],"partial":[116],"minor":[118],"cytogenetic":[119,210,225],"responses":[120],"present":[122],"44%,":[124],"22%,":[125],"8%":[127],"at":[130,179,187],"12":[131,180],"months.":[132,189],"Grade":[133],"III-IV":[134],"neutropenia,":[135],"thrombocytopenia,":[136],"anemia":[138],"developed":[139],"33%,":[141],"16%,":[142],"6%":[144],"patients,":[146],"respectively.":[147],"Sixty-five":[148],"discontinued":[150],"a":[153,202,223],"4":[156,197],"weeks":[157,198],"(1-36)":[158],"due":[159,263],"toxicity.":[161],"rate":[163,204],"(lack":[167],"accelerated/blastic":[169],"phase":[170],"persistent":[172],"response)":[173],"89.2%":[175],"(95%":[176,184],"CI:":[177,185],"84-94.4)":[178],"80.2%":[183],"72.2-88.2)":[186],"18":[188],"Platelets":[190],">":[191,196],"450x10(9)/L":[192],"discontinuation":[195,262],"associated":[200],"lower":[203],"major":[206,224],"(complete":[207],"plus":[208],"partial)":[209],"response.":[211],"Patients":[212],"Sokal's":[214],"high-risk":[215],"group":[216],"those":[218,250,257],"who":[219],"did":[220],"not":[221,258],"achieve":[222],"had":[227],"significantly":[228],"shorter":[229],"survival.":[231],"INTERPRETATION":[232],"CONCLUSIONS:":[234],"is":[236],"IFN,":[247],"especially":[248],"normal":[252],"platelet":[253],"counts":[254],"requiring":[259],"prolonged":[260],"neutropenia.":[265]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1761050310","counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
